Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.
Bibliographic record
Abstract
6574 Background: BET proteins are epigenetic readers that regulate expression of oncoproteins involved in hematologic malignancies, including MF. The oral, small-molecule BET inhibitor INCB057643 had favorable tolerability and encouraging clinical activity in pts with advanced MF in a previous Ph 1/2 trial. Methods: This ongoing Ph 1, open-label 3+3 dose-escalation/expansion study (NCT04279847) is evaluating INCB057643 monotherapy (mono; part 1; 4 mg→12 mg once daily [qd]) in adults with r/r-MF, essential thrombocythemia (ET), myelodysplastic syndrome (MDS), or MDS/myeloproliferative neoplasm (MPN) overlap syndrome, or combination therapy (combo; part 2; 4 mg qd→part 1 maximum tolerated dose) with ruxolitinib (RUX) in adults with MF and suboptimal response to RUX or who were Janus kinase inhibitor (JAKi) naive. Primary endpoint is safety/tolerability. Secondary endpoints: spleen volume (SV) response (≥35% reduction from baseline [BL; SVR35] at Week [Wk] 24), symptom response (≥50% reduction from BL in MPN-Symptom Assessment Form total symptom score [TSS50] at Wk 24), and anemia response (sustained hemoglobin increase ≥1.5 g/dL from BL [if transfusion (TF) independent at BL] or TF independence [if dependent at BL] for ≥12 wks). Results: As of 9Sep2024, 18 pts were treated in mono dose escalation, 20 in mono dose expansion, and 23 in combo dose escalation. 48 (79%) pts had MF, 5 (8%) MDS or MDS/MPN, and 8 (13%) ET. Median (range) INCB057643 exposure was 196 (15–812) days (d) in mono dose escalation, 155 (14–341) d in mono dose expansion, and 176 (25–560) d in combo dose escalation. The most common treatment (tx)-emergent adverse event (TEAE) was thrombocytopenia (TCP; 46%). Grade ≥3 TEAEs occurred in 57%, most commonly TCP (26%) and anemia (20%). Serious TEAEs occurred in 31%; 3 (5%) were tx related. No fatal events were tx related. 9 TEAEs lead to discontinuation. 2 dose-limiting toxicities occurred with mono (12 mg, TCP, hyperbilirubinemia) and 1 with combo (6 mg, TCP). 3 pts had acute myeloid leukemia transformation (4-mg mono MDS/MPN, 10-mg mono MDS, 4-mg combo MF). Wk 24 SVR35 was achieved by 3/20 evaluable MF pts treated with any mono dose (3/7 receiving ≥10 mg) and by 4/17 treated with any combo dose. Wk 24 TSS50 was achieved by 7/19 evaluable MF pts treated with any mono dose (5/8 receiving ≥10 mg) and by 8/16 treated with any combo dose. Durable anemia response occurred in 6/22 evaluable mono pts (2 TF-dependent at BL) and 4/20 combo pts. Conclusions: INCB057643 mono or combo with RUX was generally well tolerated, with no tx-related fatal events. Improvements in anemia, spleen size, and symptom burden were observed with mono and combo. Dose expansion is ongoing for 6- and 10-mg mono and 4- and 8-mg combo groups (add-on and JAKi naive). A Ph 3 study of INCB057643 mono in advanced post-JAKi MF pts is being initiated. Clinical trial information: NCT04279847 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".